Malignant neoplasm of prostate
Methodology & AI Transparency ⓘ
Malignant neoplasm of prostate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Malignant neoplasm of prostate—coded clinically as C61 across Cancer & Oncology guidelines—combines targeted/immunotherapy [Malignant neoplasm of prostate C61] with structured follow-up of Pathology / Molecular in Malignant neoplasm of prostate (C61: Genomic Staging) (Guideline-concordant surveillance (C61)).
- 2 Real-world patient consensus: Diagnostic registry C61: Malignant neoplasm of prostate is managed within Cancer & Oncology.
- 3 Typical cash cost range: Workup highlights for Malignant neoplasm of prostate (C61): targeted/immunotherapy [Malignant neoplasm of prostate C61].
- 4 Top reported side effects / signs: Longitudinal Malignant neoplasm of prostate monitoring tracks Comprehensive Metabolic & in Malignant neoplasm of prostate (C61: Organ Function Panel) toward Preserved renal/hepatic clearance (C61).
Ask our AI Specialists anything about Malignant neoplasm of prostate
What Is Malignant neoplasm of prostate?
Malignant neoplasm of prostate—coded clinically as C61 across Cancer & Oncology guidelines—combines targeted/immunotherapy [Malignant neoplasm of prostate C61] with structured follow-up of Pathology / Molecular in Malignant neoplasm of prostate (C61: Genomic Staging) (Guideline-concordant surveillance (C61)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Malignant neoplasm of prostate (C61) center on potential lymphatic or in Malignant neoplasm of prostate (C61: hematogenous dissemination if). targeted cancer & oncology interventions aim to normalize Comprehensive Metabolic & in Malignant neoplasm of prostate (C61: Organ Function Panel).
Common Symptoms & Clinical Signs
- • Presentation of Malignant neoplasm of prostate (C61): persistent painless lump, in Malignant neoplasm of prostate (C61: non-healing ulcer/mole change,)
- • Secondary Malignant neoplasm of prostate clinical sign: unintended weight loss [Malignant neoplasm of prostate C61]
- • Symptom flares in Malignant neoplasm of prostate correlating with Comprehensive Metabolic & in Malignant neoplasm of prostate (C61: Organ Function Panel) deviation outside Preserved renal/hepatic clearance (C61)
- • Functional cancer & oncology impact requiring targeted/immunotherapy [Malignant neoplasm of prostate C61] evaluation (C61)
Malignant neoplasm of prostate Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C61 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NLM Clinical Tables |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Malignant neoplasm of prostate (C61: Organ Function Panel) | Preserved renal/hepatic clearance (C61) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Malignant neoplasm of prostate (C61: Genomic Staging) | Guideline-concordant surveillance (C61) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Malignant neoplasm of prostate (C61: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C61) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Malignant neoplasm of prostate
Treatment selection for Malignant neoplasm of prostate depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Malignant neoplasm of prostate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Single-dose zoledronic acid 5 mg iv together with vitamin D may enhance resolution of bone marrow lesions over 6 weeks along with reduction of pain compared with vitamin D supplementation only. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34954857 ↗ |
| Cost-effectiveness analysis of nivolumab vs. Placebo: Which Works Better for Relapsed malignant mesothelioma? From the perspective of the Chinese healthcare system, nivolumab was not as cost-effective as placebo for relapsed malignant mesothelioma. International journal of clinical pharmacy • 2024-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37991664 ↗ |
| New Insights on Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML: What a 506-Participant Study Found However, more effective means of inhibiting BCL2 are showing promising results in combination with chemotherapy in AML. Blood advances • 2021-07-13 • Phase III Randomized Trial | N = 506 | 87/100 | PMID 34251414 ↗ |
| New Insights on Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity: What a 385-Participant Study Found Among breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low-dose candesartan might be effective to prevent an... Cancer medicine • 2021-06-15 • Phase III Randomized Trial | N = 385 | 87/100 | PMID 33998163 ↗ |
| New Insights on Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy: What a 300-Participant Study Found This RCT confirms that EPLND provides better pathological staging, while differences in early oncological outcomes were not demonstrated. European urology • 2021-05-15 • Phase III Randomized Trial | N = 300 | 87/100 | PMID 33293077 ↗ |
Malignant neoplasm of prostate Patient Community & “People Like Me” Threads
Filter Malignant neoplasm of prostate community threads and patient logs by age, biological sex, dosage, and treatment duration.